Barclays Keeps Their Buy Rating on Arcus Biosciences (RCUS)
Barclays analyst Peter Lawson maintained a Buy rating on Arcus Biosciences (RCUS) yesterday and set a price target of $35.00. The company’s shares closed last Wednesday at $26.81.
According to TipRanks.com, Lawson is a 5-star analyst with an average return of 9.3% and a 48.6% success rate. Lawson covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Springworks Therapeutics, and Karyopharm Therapeutics.
Currently, the analyst consensus on Arcus Biosciences is a Strong Buy with an average price target of $26.00, a -3.7% downside from current levels. In a report issued on May 5, Mizuho Securities also maintained a Buy rating on the stock with a $22.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $36.34 and a one-year low of $6.31. Currently, Arcus Biosciences has an average volume of 544.1K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. The firm compete in the segments of the pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.
Read More on RCUS: